CytomX Therapeutics, Inc. (CTMX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, CytomX Therapeutics, Inc. reported revenue of $76.20M, down 44.8% from the prior year. The company ran a net loss, with a net margin of -22.8%. It held $151.57M in total assets against $52.56M in total liabilities.
Key ratios (FY2025)
-29.3%
Operating margin
-22.8%
Net margin
-17.5%
Return on equity
-44.8%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $76.20M | $138.10M | $101.21M | $53.16M | $37.31M | $68.43M | $26.90M | $59.50M | $71.62M | $15.04M |
| Operating Income | -$22.36M | $25.00M | -$6.48M | -$101.33M | -$116.04M | -$80.54M | -$141.48M | -$77.87M | -$46.26M | -$59.59M |
| Net Income | -$17.37M | $31.87M | -$569.0K | -$99.32M | -$115.87M | -$64.82M | -$132.82M | -$84.60M | -$43.10M | -$58.90M |
| Total Assets | $151.57M | $120.53M | $201.79M | $260.89M | $339.41M | $358.66M | $341.28M | $457.11M | $397.64M | $199.13M |
| Total Liabilities | $52.56M | $120.99M | $249.24M | $346.64M | $339.87M | $366.44M | $290.17M | $326.23M | $327.75M | $120.65M |
| Shareholders' Equity | $99.01M | -$456.0K | -$47.45M | -$85.75M | -$459.0K | -$7.77M | $25.47M | $135.83M | $69.90M | $78.48M |
| Cash & Equivalents | $12.67M | $38.05M | $17.17M | $193.65M | $205.53M | $191.86M | $188.43M | $247.58M | $177.55M | $104.64M |
| Operating Cash Flow | -$75.59M | -$86.23M | -$56.03M | -$110.79M | -$119.03M | $5.26M | -$140.48M | -$75.52M | $170.37M | -$2.03M |
| Capital Expenditures | $220.0K | $310.0K | $840.0K | $1.74M | $1.61M | $2.31M | $3.50M | $3.79M | $1.56M | $2.18M |
| Shares Outstanding | 170.19M | 80.10M | 67.31M | 66.23M | 65.39M | 48.25M | 45.52M | 45.08M | 38.48M | 36.49M |